Accurus Biosciences

Accurus Biosciences is a private, service-oriented biotech firm specializing in antibody discovery, protein engineering, and mammalian cell-based production services. The company leverages optimized platforms for hybridoma generation, antibody humanization, stable cell line development, and transient protein expression to accelerate clients' therapeutic programs. While not developing its own drug pipeline, Accurus plays a critical supporting role in the biopharma ecosystem by providing essential R&D tools and reagents to therapeutic developers. Its business model is based on generating revenue through contracted services and product sales to research and development organizations.

Integrated suite of mammalian cell-based platforms for antibody discovery (hybridoma), protein/antibody engineering (humanization, optimization), high-yield transient and stable protein expression (using proprietary HEK293 host cells and transfection reagents), and cell-based assay development.

Accurus competes in a crowded field of service providers ranging from large, full-service CROs (Charles River, LabCorp) and CDMOs (Lonza, Samsung Biologics) to niche, specialist boutiques. Its differentiation hinges on technical expertise in antibody/protein engineering and its proprietary expression tools. Success depends on reputation, cost-effectiveness, and the ability to form strategic client partnerships.